PALO ALTO, Calif., Sept. 6 /PRNewswire/ -- New opportunities are emerging in the transdermal drug delivery market after the two largest revenue- producing patches suffered major setbacks. The market expects to sustain growth by the newest drugs launched in the central nervous system disorders segment. These new products are expected to expose new patients and physicians to the market, improving the perception and showcase the utility of transdermal patches.

Frost & Sullivan (http://www.pharma.frost.com/ ) finds that U.S. Transdermal Drug Delivery Market earned revenues of $2.97 billion in 2005 and estimates this to reach $4.47 billion in 2012.

If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants an overview of the latest analysis of the U.S. Transdermal Drug Delivery Market then send an e-mail to Melina Trevino, Corporate Communications, at melina.trevino@frost.com with the following information: your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the information via e-mail upon receipt of the above information.

"New indications previously never treated with patches such as depression, attention deficit hyperactivity disorder, and Parkinson's disease are expanding the market and providing patients with new therapies to manage their diseases," states Frost & Sullivan Industry Analyst Jason McKinnie.

Disorders of the central nervous system are providing substantial opportunity for the transdermal market. Previously CNS diseases were treated with oral or injection-based therapies, but transdermal offers advantages such as dosing control that are unavailable with other delivery methods. With patent expiration of Duragesic and recent trouble with Ortho Evra, the CNS market expects to sustain growth of the total transdermal segment until new products in other segments enter the market in 2009.

The transdermal drug delivery market is still suffering from a patent expiration and a label change that occurred in 2005. Duragesic was the largest revenue-generating patch in the market with over $1.2 billion in its last full year of patent protection. Ortho Evra underwent a label change in November 2005 that warned patients were exposed to 60% more estrogen in the patch versus the oral formulation. The then second largest product suffered dramatic revenue declines as a result. In the period of one year, the two largest revenue-generating patches dropped dramatically affecting the total transdermal market.

"In 2005, the transdermal drug delivery market suffered major setbacks to the two most revenue-generating patches. The patent expiration and label change led to a dramatic decrease in revenues for 2005 and eliminated expectations of total market growth in 2006," notes McKinnie.

Companies have an opportunity to capitalize on these setbacks by offering competitive products that utilize superior technology or enhanced safety. Patients and physicians have proven they trust transdermal technologies for pain management and birth control, and these recent setbacks offer an opportunity for new companies to enter the market space without these established competitors.

U.S. Transdermal Drug Delivery Market is part of the pharmaceutical subscription, which also includes research in the following markets: U.S. Intranasal Drug Delivery, Analysis of Top 10 Specialty Pharmaceutical Companies, and Global Pharmaceutical Contract Manufacturing Markets. All research included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.

Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit http://www.frost.com/ .

U.S. Transdermal Drug Delivery Market F791-52 Contact: Melina Trevino Corporate Communications - North America P: 210.247.2440 F: 210.348.1003 E: melina.trevino@frost.com Radhika Menon Theodore Corporate Communications - Europe P: +91 (044) 52044668 E: rmtheodore@frost.com Jasminder Kaur Corporate Communications - Asia Pacific P: 65.6890.0937 F: 65.6890.0988 E: jkaur@frost.com Surbhi Dedhia Corporate Communications - India P: +91 22 2832 4705 Ext: 131 E: sdedhia@frost.com Sharmin Jassal Corporate Communications - Australia P: +61 2 8247 8900 F: +61 2 9252 8066 E: sharmin.jassal@frost.comhttp://www.frost.com/

CONTACT: Melina Trevino, Corporate Communications - North America,
+1-210-247-2440, or fax, +1-210-348-1003, or melina.trevino@frost.com , or
Radhika Menon Theodore, Corporate Communications - Europe, +91-044-52044668,
or rmtheodore@frost.com , or Jasminder Kaur, Corporate Communications - Asia
Pacific, +65-6890-0937, or fax, +65-6890-0988, or jkaur@frost.com , or Surbhi
Dedhia, Corporate Communications - India, +91-22-2832-4705, ext. 131, or
sdedhia@frost.com , or Sharmin Jassal, Corporate Communications - Australia,
+61-2-8247-8900, or fax, +61-2-9252-8066, or sharmin.jassal@frost.com , all of
Frost & Sullivan

Web site: http://www.frost.com/
http://www.pharma.frost.com/